Pamidronate Disodium (pamidronate disodium)
Multiple manufacturers (generic); original brand: Aredia by Novartis · Bisphosphonate / Osteoclast Inhibitor
What is Pamidronate Disodium? Pamidronate disodium (brand: Aredia) is a bisphosphonate used to treat hypercalcemia of malignancy, bone metastases from breast cancer and multiple myeloma, and Paget's disease of bone. It inhibits osteoclast-mediated bone resorption.
About Pamidronate Disodium
| Brand Name | Pamidronate Disodium |
| Generic / INN | pamidronate disodium |
| Drug Class | Bisphosphonate / Osteoclast Inhibitor |
| Manufacturer | Multiple manufacturers (generic); original brand: Aredia by Novartis |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 1991 |
FDA-Approved Uses for Pamidronate Disodium
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Hypercalcemia of malignancy
- Osteolytic bone metastases of breast cancer (in combination with standard antineoplastic therapy)
- Osteolytic lesions of multiple myeloma (in combination with standard antineoplastic therapy)
- Paget's disease of bone
How Does Pamidronate Disodium Work?
Pamidronate binds to bone hydroxyapatite and inhibits osteoclast-mediated bone resorption. By reducing bone turnover, it decreases hypercalcemia of malignancy, reduces skeletal-related events (fractures, pain, spinal cord compression) from bone metastases, and slows osteolytic lesion progression in multiple myeloma.
Dosage & Administration
Hypercalcemia of malignancy: 60–90 mg IV over 2–24 hours (single dose). Breast cancer bone mets: 90 mg IV over 2 hours every 3–4 weeks. Multiple myeloma: 90 mg IV over 4 hours every 3–4 weeks. Renal function monitoring required; dose adjustments for renal impairment.
Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.
Warnings, Precautions & Side Effects
General Warning
Osteonecrosis of the jaw (ONJ) — risk increases with dental procedures; dental exam recommended before starting. Renal toxicity — single dose should not exceed 90 mg; infusion rate must be followed. Atypical femur fractures. Hypocalcemia. Embryo-fetal toxicity.
- Osteonecrosis of the jaw (ONJ)
- Renal toxicity (renal failure)
- Atypical femur fractures
- Hypocalcemia
- Embryo-fetal toxicity
Common Side Effects
- Fever
- Fatigue
- Nausea
- Hypocalcemia
- Bone pain
- Anemia
- Injection site reactions
- Hypokalemia
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Unreconstituted vials: store at room temperature 15°C to 30°C (59°F to 86°F). Reconstituted solution: refrigerate, use within 24 hours.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Pamidronate Disodium is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Pamidronate Disodium. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Pamidronate Disodium
Pamidronate is a bisphosphonate used to treat hypercalcemia of malignancy, prevent skeletal complications from bone metastases in breast cancer and multiple myeloma, and treat Paget's disease of bone.
Osteonecrosis of the jaw (ONJ) is a serious risk with bisphosphonate therapy, particularly with IV agents. Patients should have a dental exam and necessary procedures completed before starting pamidronate, and avoid invasive dental procedures during treatment.
Yes. Generic pamidronate disodium is widely available in 30 mg and 90 mg vials from multiple manufacturers. The original brand Aredia is manufactured by Novartis.
Both are IV bisphosphonates for cancer-related bone complications. Zoledronic acid (Zometa) is more potent and can be given over 15 minutes (vs. 2–4+ hours for pamidronate). In multiple myeloma, zoledronic acid has largely replaced pamidronate due to evidence of improved outcomes.
Related Medications & Conditions
Related Medications
Zometa (zoledronic acid) · Xgeva (denosumab) · Prolia (denosumab) · Calcitonin
Related Conditions
Hypercalcemia of malignancy · Multiple myeloma bone disease · Breast cancer bone metastases · Paget's disease